Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SALT LAKE CITY, Aug. 21, 2013 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., a women's healthcare company, today announced that it has completed enrollment of 5,500 women into its landmark Proteomic Assessment of Preterm Risk (PAPR) clinical study. The study has been conducted at eleven clinical centers across the U.S. and is designed to validate the performance of Sera's PreTRM™ test for the assessment of risk for preterm birth in women with singleton pregnancies.
Help employers find you! Check out all the jobs and post your resume.
SALT LAKE CITY, Aug. 21, 2013 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., a women's healthcare company, today announced that it has completed enrollment of 5,500 women into its landmark Proteomic Assessment of Preterm Risk (PAPR) clinical study. The study has been conducted at eleven clinical centers across the U.S. and is designed to validate the performance of Sera's PreTRM™ test for the assessment of risk for preterm birth in women with singleton pregnancies.
Help employers find you! Check out all the jobs and post your resume.
